Quick Answer
Monopar Therapeutics reported Total Assets of $140.72 million for the year ending 2025.
- Monopar Therapeutics showed an increase of +133.4% in Total Assets from 2024 to 2025.
- This data is from Monopar Therapeutics's annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $9.15 million | Q2 2018: $8.45 million | Q3 2018: $7.89 million | Q1 2019: $6.35 million | Q2 2019: $5.60 million | Q3 2019: $5.11 million | Q1 2020: $12.84 million | Q2 2020: $12.80 million | Q3 2020: $18.16 million | Q1 2021: $25.91 million | Q2 2021: $24.46 million | Q3 2021: $22.52 million | Q1 2022: $18.07 million | Q2 2022: $16.74 million | Q3 2022: $14.45 million | Q1 2023: $11.83 million | Q2 2023: $10.34 million | Q3 2023: $8.59 million | Q1 2024: $8.91 million | Q2 2024: $7.18 million | Q3 2024: $6.07 million | Q1 2025: $55.09 million | Q2 2025: $53.87 million | Q3 2025: $144.20 million.
- Over the full 10 years of available data (2016 to 2025), Monopar Therapeutics's Total Assets has grown by 4,759.8%.
- Historical annual values: Fiscal year 2025: $140.72 million | Fiscal year 2024: $60.29 million | Fiscal year 2023: $7.35 million | Fiscal year 2022: $13.23 million | Fiscal year 2021: $20.52 million | Fiscal year 2020: $16.87 million | Fiscal year 2019: $13.35 million | Fiscal year 2018: $7.32 million | Fiscal year 2017: $9.93 million | Fiscal year 2016: $2.90 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: